Andrew Phillips was named CEO of C4 Therapeutics, a 2016 Fierce 15 winner. Phillips has helped lead the Dana-Farber spinout’s research efforts as chief scientific officer since January 2016, and was named president later that September.
Based in Watertown, Massachusetts, C4 has focused on small-molecule treatments that target the body’s naturally occurring protein degradation pathways, aiming to trigger the destruction of disease-causing proteins from within the cell.
The company hopes the program will have a major impact on cancer and other diseases, while avoiding traditional drug resistance, and has planned to begin human testing at some point this year.
Prior to joining C4, Phillips was senior director for the Center for Development of Therapeutics at the Broad Institute of MIT and Harvard. Before that, he served as a professor of chemistry at Yale University and the University of Colorado at Boulder.
“Andy has played a key role in C4T’s growth and has helped define who we are today as a company,” Marc Cohen, co-founder and executive chairman, said in a statement. “[He] has provided exemplary leadership in recruiting a phenomenal management team, developing a robust internal pipeline of projects, and nurturing our strategic alliances with Roche and Calico.”
Early last year, C4 signed a five-year research partnership with the secretive, Google-supported Calico, focused on the diseases of aging, including cancer, with the goal of improving lifespans. And shortly after being founded, C4 announced a $750 million collaboration with Roche in January 2016, to develop its small molecule therapeutics, called degronimids, to destroy and clear harmful proteins from cells.
Meanwhile, Stewart Fisher, C4’s senior VP of discovery sciences, will take Phillips’ place as chief scientific officer.
“[Fisher’s] deep expertise in quantitative aspects of drug discovery has transformed our approach to the discovery of degraders and has provided many mechanistic insights that have enabled our internal and collaboration projects,” said Phillips.
Before joining C4, Fisher held a series of leadership roles at the Broad Institute and AstraZeneca, where he focused in target validation, drug discovery and clinical candidate support.
By Conor Hale
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
